HCA Price Prediction Next Week
Based on the provided data and recent market activity, here's the analysis and price prediction for HCA Healthcare (HCA) for the next trading week:
Technical Analysis
The stock is showing bearish momentum after a significant drop of -3.78% on Friday, closing at $313.07. Key technical indicators reveal:
- RSI at 50.63 indicates neutral territory but trending downward
- MACD at 0.31 shows weakening bullish momentum
- Stock is trading above its 20-day SMA of $306.93
- Fibonacci levels suggest immediate resistance at $323.14 and support at $302.79
Recent Events Impact
- Q4 2024 earnings released on January 24 showed mixed results:
- Revenue: $70.6B (up 8.7% YoY)
- Net income: $5.76B (up 9.9% YoY)
- EPS: $22.00 vs $19.24 YoY
- The stock faced selling pressure due to Q4 EPS coming below consensus expectations
Analyst Sentiment Multiple analysts maintain positive outlook:
- Truist Securities: Buy rating, PT $390
- Deutsche Bank: Buy rating, PT $375
- Barclays: Buy rating, PT $392
- Bank of America: Buy rating, PT $380
Price Prediction (Next Week) Based on technical and fundamental factors:
- Bearish Scenario (60% probability): Stock may test support at $302.79
- Neutral Scenario (30% probability): Consolidation between $310-$320
- Bullish Scenario (10% probability): Bounce towards $323.14 resistance
Recommendation: SELL
- Current technical weakness and post-earnings selling pressure suggest further downside
- Wait for price stabilization before considering new positions
- Target entry price: $300-305 range for long positions
HCA Similar Chart Price Prediction
The price of HCA is predicted to go up -46.56%, based on the high correlation periods with RELI. The similarity of these two price pattern on the periods is 92.82%.
HCA
RELI
Down: -46.56%Similarity: 92.82%
HCA Revenue Forecast
HCA EPS Forecast
HCA FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
HCA VS S&P500
Beyond administrative function efficiency, HCA's large scale gives it an opportunity to test and expand best practices throughout its network of facilities to improve service quality and efficiency.
HCA's focus on attractive geographic locations gives it a volume tailwind that should positively affect its top line.
The company's financial leverage should be easily manageable, giving HCA flexibility for U.S. healthcare policy changes or other shocks to the system that could constrain demand for the more elective, and highly profitable, parts of its business.
HCA Analyst's Forecast
Tim Rezvan
Keybanc
Buy
Price Target
$420 → $370
Upside
+20.05%
KeyBanc analyst Matthew Gillmor lowered the firm's price target on HCA Healthcare to $370 from $420 and keeps an Overweight rating on the shares. The firm says that its revised price target reflects elevated policy uncertainty under the incoming Trump administration.
David Macdonald
Truist Securities
Strong Buy
Price Target
$430 → $390
Upside
+31.35%
Craig Hettenbach
Morgan Stanley
Hold
Price Target
$406 → $355
Upside
+15.34%